lysine has been researched along with Peripheral Arterial Disease in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barzilay, J; Biggs, ML; Djousse, L; Garg, PK; Hirsch, C; Ix, JH; Kizer, JR; Mukamal, KJ; Newman, AB; Siscovick, DS; Tracy, RP | 1 |
Brismar, K; Kärvestedt, L; Malmstedt, J; Swedenborg, J | 1 |
Frebelius, S; Jörneskog, G; Lengquist, M; Malmstedt, J; Swedenborg, J; Wang, J | 1 |
3 other study(ies) available for lysine and Peripheral Arterial Disease
Article | Year |
---|---|
Advanced glycation end product carboxymethyl-lysine and risk of incident peripheral artery disease in older adults: The Cardiovascular Health Study.
Topics: Aged; Biomarkers; Female; Glycation End Products, Advanced; Humans; Incidence; Lysine; Male; Peripheral Arterial Disease; Prognosis; Risk Assessment; Risk Factors; Time Factors; United States | 2019 |
The receptor for advanced glycation end products and risk of peripheral arterial disease, amputation or death in type 2 diabetes: a population-based cohort study.
Topics: Aged; Amputation, Surgical; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Disease-Free Survival; Female; Humans; Incidence; Kaplan-Meier Estimate; Lysine; Male; Middle Aged; Peripheral Arterial Disease; Proportional Hazards Models; Receptor for Advanced Glycation End Products; Risk Assessment; Risk Factors; S100A12 Protein; Sweden; Time Factors | 2015 |
The Receptor for Advanced Glycation End Products (Rage) and Its Ligands in Plasma and Infrainguinal Bypass Vein.
Topics: Adult; Aged; Amputation, Surgical; Biomarkers; Diabetic Angiopathies; Disease-Free Survival; Female; Glycation End Products, Advanced; Humans; Kaplan-Meier Estimate; Ligands; Lysine; Male; Middle Aged; Peripheral Arterial Disease; Proportional Hazards Models; Prospective Studies; Receptor for Advanced Glycation End Products; Reoperation; Risk Factors; S100A12 Protein; Time Factors; Treatment Outcome; Up-Regulation; Vascular Grafting; Veins | 2016 |